American Journal of Kidney Diseases
Volume 55, Issue 2 , Pages 217-222 , February 2010

The 2009 Proposed Rule for Prospective ESRD Payment: Historical Perspectives and Public Policies—Bundle Up!

  • Daniel E. Weiner, MD, MS

      Affiliations

    • Tufts Medical Center, Boston, Massachusetts
    • Corresponding Author InformationAddress correspondence to Daniel E. Weiner, MD, MS, Tufts Medical Center, 800 Washington St, Box #391, Boston, MA 02111
    • ,
  • Suzanne G. Watnick, MD

      Affiliations

    • Portland Veterans Affairs Medical Center, Portland, Oregon

References 

  1. Collins AJ, Foley RN, Herzog C, et al. Excerpts from the US Renal Data System 2009 annual data report. Am J Kidney Dis. 2010;55(suppl 1):S1–S420
  2. Medicare Improvements for Patients and Providers Act of 2008. Medicare, Provisions Relating to Part B, Other Payment and Coverage Improvements. Public L No. 110-275, §153(a).
  3. Centers for Medicare & Medicaid Services. End-stage renal disease prospective payment system proposed rules. Fed Regist. 2009;74(187):49922–50102
  4. Nissenson AR, Mayne TJ, Krishnan M. The 2009 proposed rule for prospective ESRD payment: perspectives from a large dialysis organization. Am J Kidney Dis. 2010;55(2):223–226
  5. Moran J. The 2009 proposed rule for prospective ESRD payment: perspectives from a medium-sized dialysis organization. Am J Kidney Dis. 2010;55(2):227–228
  6. Sadler JH. The 2009 proposed rule for prospective ESRD payment: perspectives from a not-for-profit small dialysis organization. Am J Kidney Dis. 2010;55(2):229–230
  7. Bhat JG, Bhat P. The 2009 proposed rule for prospective ESRD payment: perspectives from a for-profit small dialysis organization. Am J Kidney Dis. 2010;55(2):231–233
  8. Kristensen C, Wish J. The 2009 proposed rule for prospective ESRD payment: perspectives from the Forum of ESRD Networks. Am J Kidney Dis. 2010;55(2):234–236
  9. Blagg CR. The early history of dialysis for chronic renal failure in the United States: a view from Seattle. Am J Kidney Dis. 2007;49(3):482–496
  10. Rettig RA. Origins of the Medicare kidney disease entitlement: the Social Security Amendments of 1972. In:  Hanna KE editors. Biomedical Politics. Washington, DC: National Academy Press; 1991;p. 176–214
  11. Rettig R, Levinsky N Committee for the Study of the Medicare End-Stage Renal Disease Program. Kidney Failure and the Federal Government. Washington, DC: Division of Health Care Services; 1991;
  12. Lockridge RS. The direction of end-stage renal disease reimbursement in the United States. Semin Dial. 2004;17(2):125–130
  13. Beusterien KM, Nissenson AR, Port FK, et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996;7(5):763–773
  14. Evans RW, Rader B, Manninen DL Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA. 1990;263(6):825–830
  15. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25(4):548–554
  16. Sisk JE, Gianfrancesco FD, Coster JM. Recombinant erythropoietin and Medicare payment. JAMA. 1991;266(19):247–252
  17. de Lissovoy G, Powe NR, Griffiths RI, et al. The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. Med Care. 1994;32(2):130–140
  18. General Accounting Office. End Stage Renal Disease: Bundling Medicare's Payment for Drugs with Payment for all ESRD Services Would Promote Efficiency and Clinical Flexibility. US Government Accountability Office; November 2006. GAO-07-77.
  19. Collins AJ, Ebben JP, Gilbertson DT. EPO adjustments in patients with elevated hemoglobin levels: provider practice patterns compared with recommended practice guidelines. Am J Kidney Dis. 2007;49(1):135–142
  20. Thamer M, Zhang Y, Kaufman J, et al. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007;297(15):1667–1674
  21. Steinbrook R. Medicare and erythropoietin. N Engl J Med. 2007;356(1):4–6
  22. Office of Inspector General. Medicare Reimbursement for Existing End-Stage Renal Disease Drugs. US Dept of Health and Human Services; 2004;OEI-03-04-00120
  23. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public L No. 108-173.
  24. Leavitt MO US Department of Health and Human Services. Report to Congress: a design for a bundled end stage renal disease prospective payment system (Published 2008). http://www.cms.hhs.gov/ESRDGeneralInformation/Downloads/ESRDReportToCongress.pdfAccessed November 10, 2009
  25. Medicare Coverage for End-Stage Renal Disease Patients (Compilation of the Social Security laws including the Social Security Act, as amended, and related enactments through January 1, 2009). http://www.ssa.gov/OP_Home/ssact/title18/1881.htm#ft576Accessed November 10, 2009

 This article is part of a series in the February 2010 issue of AJKD that explores the 2009 proposed rule for the Medicare ESRD prospective payment system.

PII: S0272-6386(09)01574-1

doi: 10.1053/j.ajkd.2009.12.005

American Journal of Kidney Diseases
Volume 55, Issue 2 , Pages 217-222 , February 2010

Article Tools

* Image Usage & Resolution